C4X Discovery Holdings plc, of Manchester, U.K., said that its C4X-3256 program has been awarded a grant from the National Institute on Drug Abuse of about $480,000 that will support preclinical development of the candidate in cocaine use disorder. The oral orexin-1 receptor antagonist was recently licensed to Indivior UK Ltd.